Bio
Former Chairman of Department of Pathology CRO Aviano - “S. Maria degli Angeli” Pordenone Hospital, and Scientific Director CRO Aviano. He was a Member of WHO International Agency for Research on Cancer (IARC), Monograph Working Group on Biological Agents, Lyon 2019. He is the Chairman of the Italian TNM Staging Committee UICC; He is a Member of the Scientific Board of the EORTC Pathobiology Group, and Chairman of the Hematological subgroup Editor-in-Chief of Hemato, an International Open Access Journal of Hematology Field of interest: Lymphoma classification; Hodgkin lymphoma; non-Hodgkin lymphoma; tumor microenvironemt; HIV-associated lymphomas; EBV-associated lymphomas; KSHV/HHV8- associated lymphomas. Methods of research: Immunohistochemistry; multiplexing immunohistochemistry; in situ hybridization; cell culture; cell lines; secretoma; digital pathology.

Bio
Jude Fitzgibbon, PhD, is a Professor of Personalized Cancer Medicine at the Barts Cancer Institute, Queen Mary University of London where he leads the Centre for Cancer Genomics and Computational Biology. His research is focused on the genetic and epigenetic changes responsible for the development and progression of leukaemia and lymphomas and the evaluation of therapeutic strategies to reverse these changes. His team has uncovered a highly complex pattern of lymphoma evolution, consistent with the existence of a common progenitor B cell from which each new episode of disease is thought to arise and has an internationally recognised programme on familial forms of myeloid leukaemia. He received his Bachelor of Arts in Genetics from Trinity College Dublin in 1989 before going on to receive his Doctor of Philosophy at University College London in 1993. He holds numerous leadership roles including: the Chair of the UK’s National Cancer Research Institute Lymphoma Science Subgroup, the Chair of the Danish Cancer Grants Committee, is an Associate Editor for the British Journal of Haematology and a Male Change Champion, for the international alliance, Woman in Lymphoma.

Bio
Dr. Mbulaiteye is a senior investigator in the Infections and Immunoepidemiology Branch (IIB). He conducts research to understand the etiology of Burkitt lymphoma (BL), a cancer that occurs worldwide but has its highest incidence recorded in populations of sub-Saharan Africa. Dr. Mbulaiteye received physician training at Makerere University, Kampala (1990) with advanced training in epidemiology and biostatistics (M.Phil.) from the University of Cambridge, U.K. (1994), and specialist training in internal medicine (M.Med.) from Makerere University (1996). His early research focused on measuring the impact of HIV on cancer in patients at the Uganda Cancer Institute (1994-1997) and investigating population trends of HIV in a general population in rural southwest Uganda while at the Uganda Virus Research Institute/ U.K. Medical Research Council HIV program. Dr. Mbulaiteye joined IIB in December 2000 to focus his work on KS and BL as a research fellow, and was awarded NIH scientific tenure and appointed senior investigator in 2013. Dr. Mbulaiteye is an active member of the NIH and NCI community, and has served on various search and technical committees. He is currently a member of DCEG Genotyping Review Committee. He is the Co-Editor-in-Chief, Infectious Agents and Cancer, Editorial Board Member for AIDS, International Journal of Cancer, and Frontiers in Cancer Epidemiology and Prevention. He is a member of the African Organization for Research and Training in Cancer (AORTIC), the Darwin College Society, the Cambridge Commonwealth Trust, and the World Federation of Scientists.

Bio
Anna Sureda, (MD, PhD) is nowadays the Head of the Clinical Hematology Department of Institut Català d’Oncologia – Hospitalet, Barcelona. She had previously been a Senior Consultant in Hospital de la Santa Creu i Sant Pau, Barcelona (from January 1991 to December 2010) and a Senior Consultant focused in lymphomas and hematopoietic stem cell transplantation (HSCT) at Addenbrookes–Cambridge University Hospital, UK (December 2010 – December 2012). Anna Sureda has focused her career on clinical investigations into the treatment of Hodgkin’s lymphoma, non-Hodgkin’s lymphoma and multiple myeloma patients evaluating novel therapies such as immunotherapy combined with stem-cell transplantation. Anna Sureda was appointed Chairperson of the Lymphoma Working Party (LWP) of the European Group for Blood and Marrow Transplantation (EBMT) from March 2004 to March 2010 and Secretary of the same organization from March 2010 to March 2016. She was elected co-chair of the Lymphoma Committee of the Center for International Blood and Marrow Transplant Research (CIBMTR) and has served the organization in this position from February 2015 to February 2019. She was subsequently appointed as member of a large non-US Transplant Center in the Advisory Committee of the CIBMTR (from February 2019). Anna Sureda is President of the Spanish Society of Hematopoietic Stem Cell Transplantation and Cellular Therapy (GETH-TC) and, from March 2021, President Elect of the EBMT. Anna Sureda is regular reviewer of several peer reviewed journals (Blood, Annals of Oncology, Bone Marrow Transplantation, The Hematology Journal, The European Journal of Hematology y Annals of Hematology) and has co-authored more than 400 manuscripts.

Bio
Dr. Fina Climent, MD, PhD, is Pathologist in the Department of Pathology at the University Hospital of Bellvitge, Barcelona, Spain. She graduated in Medicine at the University of Rovira i Virgili in Tarragona, Spain, going on to specialize in Pathology at Hospital of Bellvitge. She completed her training as hematopathologist with Dr. Elaine Jaffe at the National Institutes of Health (NIH) in Bethesda, MD. She went on to do a doctorate in Medicine and Surgery in 2021, at the University of Barcelona. Dr. Climent has been working as Senior Consultant Hematopathologist at Hospital of Bellvitge for the last 17 years. Currently, she is the responsible for hematopathologist diagnosis in the Functional Unit of Lymphomas located at Institut Català d’Oncologia (ICO) in Barcelona. She is also acting as the Scientific Director of the HUB-ICO-IDIBELL biobank and the Quality Manager of the Department of Pathology. Dr. Climent is an active member of the national and international pathology societies. She is currently the President of the Catalan Society of Pathology. She has authored or co-authored more than 50 papers related to Hematopathology and she is a frequent speaker at national and international meetings and conferences. Dr. Climent lives in Tarragona with her husband and their three children.

Bio
Elaine S Jaffe is a Senior Investigator and a named NIH Distinguished Investigator at the National Cancer Institute. She completed her medical studies at Cornell University Medical College and the University of Pennsylvania. Dr. Jaffe is an author of more than 700 peer reviewed articles, 150 chapters and invited reviews and more than 40 Editorials. She was an Editor for the WHO Classification of Tumors of the Hematopoietic and Lymphoid Tissues. Science Watch named her among the 10 most highly cited researchers in clinical oncology, and she was included among the 400 most highly cited researchers in Biomedical Science worldwide between 1996 and 2011. Dr. Jaffe has held leadership positions in several major medical societies, including the American Society of Hematology, United States and Canadian Academy of Pathology and the Society for Hematopathology. Dr. Jaffe was Chair, of the Medical Sciences Section, of the American Association for the Advancement of Science. In 2008 she was elected to the Institute of Medicine of the National Academies (now the National Academy of Medicine - NAM) and was subsequently appointed Chair of the Section 4 Membership Committee of NAM, with responsibility for Internal Medicine, Pathology and Dermatology. In 2013 Dr. Jaffe was awarded the Stratton Medal from the American Society of Hematology. Dr Jaffe was invited to give the Henry Rappaport Memorial Lecture at the Lugano International Congress on Malignant Lymphoma in 2013, and in 2016 she received the Rous Whipple Award from the American Society of Investigative Pathology (ASIP). The United States and Canadian Academy of Pathology honored her with the Distinguished Pathologist Award in 2019. In 2022 she will be presented with the Gold Headed Cane Award, the highest honor from the ASIP. Throughout her career, her clinical and investigational studies have been intertwined to enhance our understanding of the malignant lymphomas.